ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Operating Income: kr-43.55 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EXPRS2 ExpreS2ion Biotech Holding AB OSTO:EXPRS2
43 GF Score
Price kr1.43
GF Value kr3.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Operating Income?

ExpreS2ion Biotech Holding AB OSTO:EXPRS2 43 Operating Income is kr-43.55 Mil as of Mar. 2026. GuruFocus rates OSTO:EXPRS2 with a GF Score™ of 43/100 and a GF Value™ of kr3.42 (Possible Value Trap). The stock has 5 warning signs investors should review.

ExpreS2ion Biotech Holding AB's Operating Income for the three months ended in Mar. 2026 was kr-11.94 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr-43.55 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. ExpreS2ion Biotech Holding AB's Operating Income for the three months ended in Mar. 2026 was kr-11.94 Mil. ExpreS2ion Biotech Holding AB's Revenue for the three months ended in Mar. 2026 was kr1.04 Mil. Therefore, ExpreS2ion Biotech Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 was -1,150.39%.

Warning Sign:

ExpreS2ion Biotech Holding AB operating margin has been in a 5-year decline. The average rate of decline per year is -26.6%.

ExpreS2ion Biotech Holding AB's 5-Year average Growth Rate for Operating Margin % was -26.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 was -125.61%. ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12,889.85%.


ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-47.764 * ( 1 - 20.45% )/( (31.793 + 28.708)/ 2 )
=-37.996262/30.2505
=-125.61 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-47.628/( ( (0.465 + max(-18.816, 0)) + (0.274 + max(-12.677, 0)) )/ 2 )
=-47.628/( ( 0.465 + 0.274 )/ 2 )
=-47.628/0.3695
=-12,889.85 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.189 + 0 + 7.752) - (4.044 + 0 + 23.713)
=-18.816

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.025 + 0 + 8.745) - (1.642 + 0 + 20.805)
=-12.677

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

ExpreS2ion Biotech Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.941/1.038
=-1,150.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ExpreS2ion Biotech Holding AB Operating Income Related Terms


ExpreS2ion Biotech Holding AB Operating Income Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Operating Income Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.40 -127.61 -105.97 -67.70 -44.27

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.66 -11.68 -9.75 -10.18 -11.94
OSTO:EXPRS2
43GF Score
ExpreS2ion Biotech Holding AB OSTO:EXPRS2
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-43.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of kr-43.55 Mil mean?
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Operating Income of kr-43.55 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Operating Income too high?
ExpreS2ion Biotech Holding AB's current Operating Income is kr-43.55 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Operating Income compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Operating Income of kr-43.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Operating Income is kr-43.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.42, compared to a current price of kr1.43 — trading 58.2% below its estimated fair value. The current Operating Income is kr-43.55 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Operating Income is kr-43.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of kr1.43 is trading 58.2% below its estimated GF Value™ of kr3.42. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:EXPRS2:

  • Operating Income: kr-43.55 Mil
  • GF Value™: kr3.42 vs. price of kr1.43 (58.2% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges 5JD0:Germany
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for OSTO:EXPRS2

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.43
Price
kr3.42
GF Value